Side-by-side · Research reference

GDF-8vsMGF

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED23/48 cited

BAnimal-StrongHUMAN-REVIEWED14/55 cited

GDF-8

TGF-β Superfamily · Negative Muscle Regulator

15–20%Muscle mass gain (MSTN−/−)

↓ AdiposityFat reduction (loss-of-function)Herman 2026 Jacquez 2026

No adversePhenotype (genetic null)Jacquez 2026

Not administered — research target for inhibition

MGF

IGF-1Ec Splice Variant · Muscle-Specific

IGF-1EcSplice variantArmakolas 2016

24-AASynthetic E-domain

Animal onlyHuman evidence

SQ · Research context only

01Mechanism of Action

Parameter

GDF-8

MGF

Primary target

Activin type II receptors (ActRIIA/B) on skeletal muscleIglesias 2026

Satellite cells (Pax7+) in skeletal muscleMoore 2018

Pathway

MSTN → ActRII/TGFBR1 → Smad2/3 signaling → muscle protein synthesis suppression

Mechanical stress → IGF-1Ec mRNA upregulation → Local E-domain peptide release → Satellite cell activation

Downstream effect

Restricts muscle hypertrophy, limits satellite cell activation, increases proteolysis via ubiquitin-proteasome and autophagy pathwaysGong 2026 Iglesias 2026

Satellite cell proliferation, myoblast differentiation, muscle fiber repair

Feedback intact?

Yes — part of muscle-pituitary endocrine axis; muscle-derived MSTN influences FSH synthesisIglesias 2026

—

Origin

Endogenous myokine secreted by skeletal muscle; circulates systemically as latent complexIglesias 2026

Alternative splicing of IGF-1 gene (exons 4-6) produces IGF-1Ec precursor; E-domain cleaved post-translationallyArmakolas 2016 Vassilakos 2017

Antibody development

—

02Dosage Protocols

Parameter

GDF-8

MGF

Clinical use

None — MSTN is a research target for inhibition, not a therapeutic peptide administered to humans

Sold by research suppliers (e.g., CertaPeptides) for in vitro / animal studies only.

—

Inhibition strategies

Monoclonal antibodies, VLP-based active immunotherapy, gene editing (CRISPR)

—

VLP immunogen (MS2.87-97)

Active immunization protocol in mice — elicits anti-MSTN antibodies without GDF11 cross-reactivityJacquez 2026

Reduces body fat, increases muscle mass and grip strength; no major safety concerns in animal models.Jacquez 2026

—

Dual immunization (MSTN + Activin A)

Combined active immunization in GH-deficient miceMansoor 2026

Improves skeletal muscle performance beyond single-target inhibition.Mansoor 2026

—

Gene editing outcomes

Precision CRISPR edits produce double-muscle phenotype, improved carcass quality in livestock

Pleiotropic effects on metabolism, reproduction, and welfare require systematic evaluation.

—

Synthetic peptide

—

24-amino-acid E-domain sequence

Corresponds to human IGF-1Ec exons 4-6 region.

Rodent cardiac model

—

200 μg/kg via peptide-eluting microstructures

Post-MI injection; improved ejection fraction by 8 weeks.

Acute delivery (mouse MI)

—

Single bolus within 12 hrs post-infarctionShioura 2014

Delayed decompensation; no human protocol established.

Human evidence

—

None — no published clinical trials

All dosing extrapolated from animal models.

Detection in doping

—

Full-length MGF detected via LC-MS in illicit productsThevis 2014

WADA-prohibited since 2005; no therapeutic indication.

Evidence basis

—

Animal models + in vitro only

03Metabolic / Fat Loss Evidence

Parameter

GDF-8

MGF

Primary mechanism

MSTN loss-of-function reduces fat accumulation independent of muscle mass effects

—

Human genetic evidence

Humans with MSTN function-disrupting variants have increased muscle mass, strength, and reduced adiposityHerman 2026

—

Animal model outcomes

VLP-immunized mice: reduced age-associated weight gain, significantly lower body fat by DEXAJacquez 2026

—

Adipose-muscle crosstalk

MSTN modulates myostatin-TAZ signaling; inhibition shifts adipose expansion toward hyperplasiaLi 2026

—

Metabolic benefits

Improved metabolic health in genetic MSTN null modelsJacquez 2026

—

Age-related effects

MSTN upregulation linked to age-dependent muscle atrophy and fat accumulation

—

04Side Effects & Safety

Parameter

GDF-8

MGF

Genetic null phenotype

No known adverse phenotypes in humans or mice with MSTN loss-of-functionJacquez 2026

—

Antibody cross-reactivity risk

Non-selective inhibitors may block GDF11, affecting cardiac and neural function

—

VLP immunotherapy safety

No major safety concerns in mice; rare hypersensitivity possibleJacquez 2026

—

Echocardiography

No cardiac abnormalities detected in MSTN-immunized miceJacquez 2026

—

Pleiotropic effects (gene editing)

MSTN editing may affect reproductive performance, metabolic homeostasis, and animal welfare

—

Assay variability

Circulating MSTN levels often fail to mirror intramuscular changes; clinical interpretation challengingIglesias 2026

—

Human safety data

—

None — no clinical trials published

Theoretical IGF-1 axis risk

—

Chronic IGF-1Ec overexpression linked to cancer progression (prostate, colorectal, breast)

Tumor promotion

—

IGF-1Ec overexpressed in osteosarcoma, colorectal polyps with dysplasia, endometrial cancer

Antibody development

—

Unknown — no longitudinal human exposure data

Local injection reaction

—

Presumed similar to other peptides (erythema, induration) — no direct evidence

Dysregulated expression with age

—

Older adults (70+ yrs) show blunted IGF-1Ec response post-exercise vs youngMoore 2018

Absolute Contraindications

GDF-8

·Not applicable — MSTN is not administered as a therapeutic agent

MGF

·Active malignancy or history of IGF-1-sensitive cancers (prostate, colorectal, breast, osteosarcoma)
·No established therapeutic use — investigational only

Relative Contraindications

GDF-8

·Inhibition strategies contraindicated in conditions requiring maintained muscle proteostasis (theoretical)

MGF

·Family history of IGF-1-axis malignancies
·Use outside research setting

05Administration Protocol

Parameter

GDF-8

MGF

1. Research context only

GDF-8 (myostatin) is not administered to humans. It is studied as a target for inhibition using monoclonal antibodies, active immunotherapy (VLP-based vaccines), or gene editing (CRISPR). Research-grade peptide supplied by vendors like CertaPeptides is intended for in vitro and animal studies only.

MGF (E-domain peptide) has no approved clinical protocol. All published data derive from animal models or in vitro experiments.

2. Inhibition strategies

Clinical development focuses on blocking MSTN activity via: (1) neutralizing monoclonal antibodies targeting mature MSTN or ActRII receptors; (2) active immunotherapy generating endogenous anti-MSTN antibodies (e.g., MS2.87-97 VLP platform); (3) precision gene editing to disrupt MSTN expression in livestock or therapeutic contexts.

Commercially available MGF corresponds to the 24-amino-acid human E-domain (hEc). Rodent E-domain (Eb) is structurally distinct and not interchangeable.

3. VLP immunization protocol (animal model)

MS2.87-97 VLP administered to mice elicits anti-MSTN antibodies targeting a discrete epitope in mature MSTN protein. Immunization schedule and dose optimized for sustained antibody response without GDF11 cross-reactivity. No human protocols established.Jacquez 2026

Rodent studies used peptide-eluting polymeric microstructures (cardiac) or direct intramuscular injection. Routes and doses non-translatable to humans.Peña 2015 Shioura 2014

4. Gene editing considerations

CRISPR-mediated MSTN knockout produces double-muscle phenotype in livestock (cattle, swine, sheep). Ethical frameworks and welfare assessments required; pleiotropic effects on reproduction, metabolism, and health must be systematically evaluated before human translation.

MGF peptides prohibited in sport since 2005. Detection via LC-MS established for full-length MGF products.Thevis 2014

5. Research context only

—

Any human use falls outside approved medical practice and regulatory frameworks. No safety or efficacy data exist.

06Stack Synergy

GDF-8

— no documented stacks

MGF

+ BPC-157

Multi-pathway

View BPC-157 →

MGF activates satellite cells for muscle fiber repair; BPC-157 promotes angiogenesis, collagen synthesis, and tendon healing via distinct pathways (VEGF, FAK, integrin signaling). Theoretical synergy in post-injury contexts combines myogenic (MGF) and stromal (BPC-157) repair mechanisms. Both lack human validation.

MGF: No established dose
BPC-157: 250–500 mcg SQ near injury site
Context: Animal models only
Primary benefit: Theoretical multi-tissue repair (muscle + tendon/ligament)

+ TB-500

Moderate

View TB-500 →

TB-500 (thymosin beta-4 fragment) enhances actin polymerization, cell migration, and angiogenesis—complementary to MGF satellite cell activation. Both upregulated post-injury; combined use presumed additive for muscle regeneration in preclinical models.

MGF: No established dose
TB-500: 2–5 mg SQ weekly
Context: Animal models only
Primary benefit: Satellite cell activation + enhanced migration/angiogenesis